THERAPEUTIC RADIOPHARMACEUTICALS

Policy Number: 2019T0593A  Effective Date: January 1, 2019

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVERAGE RATIONALE</td>
<td>1</td>
</tr>
<tr>
<td>DEFINITIONS</td>
<td>1</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>2</td>
</tr>
<tr>
<td>DESCRIPTION OF SERVICES</td>
<td>2</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
<td>2</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION</td>
<td>4</td>
</tr>
<tr>
<td>CENTERS FOR MEDICARE AND MEDICAID SERVICES</td>
<td>5</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>5</td>
</tr>
<tr>
<td>POLICY HISTORY/REVISION INFORMATION</td>
<td>6</td>
</tr>
<tr>
<td>INSTRUCTIONS FOR USE</td>
<td>6</td>
</tr>
</tbody>
</table>

COVERAGE RATIONALE

Lutathera® (lutetium Lu 177 dotatate) injection for intravenous use is proven and medically necessary for the treatment of somatostatin receptor-positive metastatic or unresectable locally advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults, who have progressed on a high dose somatostatin analog (e.g., long acting octreotide, lanreotide).

Lutathera® (lutetium Lu 177 dotatate) injection for intravenous use is unproven and not medically necessary for ALL other indications.

Radium-223, Xofigio is proven and medically necessary when ALL of the following criteria are met:

- Individual has metastatic, castration-resistant prostate cancer (mCRCP); and
- Individual has bone metastases documented on imaging; and
- Individual is not/will not be receiving concurrent chemotherapy, biologic therapy, or immunotherapy (concurrent use of hormonal therapy is permitted); and
- Individual has no current visceral metastatic disease.

Radium-223 (Xofigo®) is unproven and not medically necessary for all other indications because its effectiveness for indications other than listed above has not been established.

DEFINITIONS

Carcinoid Syndrome: Carcinoid syndrome is a constellation of symptoms resulting from hormones secreted by carcinoid tumors. These tumors can either be active or inactive. Active tumors secrete various hormones and vasoactive peptide substances such as adrenocorticotropic hormone (ACTH), serotonin, histamine, and tachykinins.

Lutathera® (lutetium Lu 177 dotatate): is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NET’s), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Neuroendocrine Tumor (NET): A tumor that forms from cells that release hormones into the blood in response to a signal from the nervous system. NETs may make higher-than-normal amounts of hormones, which can cause many different symptoms. These tumors may be benign (not cancerous) or malignant (cancerous) (NCI, 2018).

Radium-223 (Xofigo®): Is an alpha-emitting radiotherapeutic drug. Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.

Somatostatin-Receptor Scintigraphy (SRS): A type of radionuclide scan used to find carcinoid and other types of tumors. Radioactive octreotide, a drug similar to somatostatin, is injected into a vein and travels through the
bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin. A radiation-measuring device detects the radioactive octreotide, and takes pictures showing where the tumor cells are in the body; also called octreotide scan (NCI, 2018).

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A9513</td>
<td>Lutetium Lu 177, dotatate, therapeutic, 1 mCi</td>
</tr>
<tr>
<td>A9606</td>
<td>Radium RA-223 dichloride, therapeutic, per microcurie</td>
</tr>
<tr>
<td>A9699</td>
<td>Radiopharmaceutical, therapeutic, not otherwise classified</td>
</tr>
</tbody>
</table>

**DESCRIPTION OF SERVICES**

Therapeutic radiopharmaceutical agents are radioactive chemicals or drugs that have a specific affinity for a particular body tissue or organ. These agents are used alone and in conjunction with therapies to treat radiation-sensitive diseases.

**Lutathera® (lutetium Lu 177 dotatate)**

Lutathera® (lutetium Lu 177 dotatate) is a targeted form of radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults. Lutetium Lu 177 dotatate binds to a part of a cell called a somatostatin receptor, which may be present on certain tumors. After binding to the receptor, the drug enters the cell allowing radiation to cause damage to the tumor cells.

Neuroendocrine tumors (NETs) comprise a broad family of rare tumors which can arise from neuroendocrine cells in the diffuse neuroendocrine system anywhere in the body. Variations in clinical manifestations and biological characteristics of different NETs negatively impact timely diagnosis. Consequently, patients with NETs are often diagnosed only in their metastatic stage of malignancy. Late stage diagnosis further results in significant accrued morbidity burden and in a reduced survival rate (Dasari, 2017; National Cancer Institute [NCI], 2018; National Comprehensive Cancer Network [NCCN], 2018).

**Radium-223 (Xofigo®)**

Xofigo (radium-223 dichloride) injection (Bayer HealthCare Pharmaceuticals Inc.), initially called Alpharadin, is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases but no visceral metastases. It is a radioactive therapeutic agent that mimics calcium and selectively binds to areas of bone-repairing activity, forming complexes with bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases (Cheetham and Petrylak, 2012; Bayer HealthCare Pharmaceuticals Inc., 2013; Parker et al., 2013a).

Prostate cancer (PC) is the most common cancer in men and the second leading cause of cancer death in men. The annual incidence in the United States is approximately 242,000. Castration-resistant prostate cancer (CRPC) is defined by rising levels of prostate-specific antigen (PSA) in spite of androgen deprivation therapy and castrate levels of serum testosterone. Xofigo® (radium-223 dichloride) injection (Bayer HealthCare Pharmaceuticals Inc.) is intended for the treatment of patients with castrate-resistant prostate cancer (CRPC) with symptomatic bone metastases, and no visceral metastases. It is an alpha particle-emitting radioactive therapeutic agent that targets bone metastases by selectively binding to areas of bone-repairing activity, causing double-stranded breaks in DNA, but minimizing the effect on adjacent, healthy tissue (Hayes, Archived 2016).

**CLINICAL EVIDENCE**

**Lutathera® (lutetium Lu 177 dotatate)**

Early case series and retrospective studies report that treatment of advanced GEP-NETs with lutetium Lu 177 dotatate was associated with tumor response, improved survival outcomes (such as, stable disease, tumor regression, or...
longer median time to progression), and quality of life (Delpassand, 2014; Ezziddin, 2014; Kwekkeboom, 2003; Kwekkeboom, 2005; Kwekkeboom, 2008; Sabet, 2014; Sabet, 2015; Teunissen, 2004).

In January 2018, the U.S. Food and Drug Administration approved Lutathera (lutetium Lu 177 dotate) for the treatment of somatostatin receptor-positive GEP-NETs in adults, largely based on support from the NETTER-1 trial.

Strosberg et al. (2017) conducted an open-label, multicenter randomized, controlled trial to evaluate the efficacy and safety of lutetium-177(Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors were randomized to receive either Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol. At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the Lu-Dotatate group versus 3% in the control group. The authors concluded that treatment with Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the Lu-Dotatate group.

Brabander et al. (2017) reviewed a long-term safety and survival in an investigator-sponsored, open-label, single-arm, single-institution (Erasmus) retrospective study of over 1200 patients with somatostatin receptor-positive neuroendocrine tumors who received Lu-DOTATATE treatment. Primary tumor sites included bronchus, foregut, midgut, hindgut, pancreas, and unknown. Patient populations were heterogeneous for baseline tumor status (progressive versus nonprogressive) and treatments received prior to Lu-DOTATATE. Of these patients, the safety analysis included 610 patients, 360 (60%) of which had metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), treated with a cumulative dose of at least 100 mCi (3.7 GBq) of lutetium Lu-177DOTATATE. Long-term toxicity included acute leukemia in four patients (0.7%) and myelodysplastic syndrome in nine patients (1.5%). There was no therapy-related long-term renal or hepatic failure. Overall response rate, defined as complete or partial response, in patients with midgut and pancreatic NETs with progressive disease at baseline was 84% and 81%, respectively. Median overall survival for GEP-NETs was only reported for pancreas (71 months) and midgut (60 months), due to small numbers of other gastrointestinal primaries. A subset analysis of PFS in patients with midgut tumors and progressive disease at baseline was 24 months.

**Professional Societies**

**National Comprehensive Cancer Network (NCCN)**

The National Comprehensive Cancer Network’s clinical practice guideline on “Neuroendocrine and Adrenal Tumors” (NCCN, 2018) recommends use lutetium Lu 177-dotate for the treatment of somatostatin receptor-positive metastatic or unresectable locally advanced gastroenteropancreatic neuroendocrine tumors (NET), including foregut, midgut, and hindgut NET in adults who have progressed on octreotide or lanreotide.

Based on the clinical literature review from the studies noted below the evidence is sufficient to determine that treatment with lutetium Lu 177 dotate results in meaningful improvement in net health outcomes for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut (gastroduodenal), midgut (distal small intestine and proximal colon), and hindgut (distal colorectal and pancreas) neuroendocrine tumors in adults.

**Radium-223 (Xofigo®) for Treatment of Bone Metastases in Castration-Resistant Prostate Cancer (CRPC)**

Nilsson, et al. (2012) examined the dose-response relationship and pain-relieving effect of Ra-223. A total of 100 patients with CRPC and painful bone metastases were randomized to Ra-223 vs. placebo. The primary end-point was pain index (visual analog scale [VAS] and analgesic use); pain index was also used to classify patients as “responders” or “non-responders”. A significant dose response for pain index was noted at week 2, as well as week 8. The authors concluded that pain response was seen in up to 71 % of the patients with a dose response observed 2 weeks after administration; and the side effect profile of Ra-223 previously reported was confirmed, finding it to be well tolerated.

In a phase II, randomized, placebo-controlled study, Nilsson, et al. (2013) evaluated the safety and effectiveness of Ra-223 in patients with CRPC and painful bone metastases. The authors reported the 24-month OS and safety data from the period 12 to 24 months after the first injection of study medication. Patients with CRPC and bone pain were randomized 1:1 to receive 4 injections of Ra-223 (50 kBq/kg or placebo after external-beam radiotherapy; each injection was given every 4 weeks. End-points for this report were 24-month OS, long-term safety, and treatment-
related adverse events (AEs) occurring in the 12- to 24-month period. After 24 months, 10 (30 %) patients were alive in the Ra-223 group compared with 4 patients (13 %) in the placebo group. Patients who received at least 1 dose of study medication had a median OS of 65 weeks in the Ra-223 group versus 46 weeks in the placebo group. The authors concluded that Ra-223 had a highly favorable safety profile, with no evidence of second malignancies at 24-month follow-up. The significant improvement in OS observed in patients receiving Ra-223 versus placebo suggested that treatment of bone disease with Ra-223 has survival benefits.

Parker et al. (2013a) performed a phase II, double-blind, multi-center clinical trial prospectively which evaluated the safety and effectiveness of 3 different doses of Ra-223 in patients with CRPC and bone metastases. A total of 122 patients were randomized to receive 3 injections of Ra-223 at 6-week intervals, at doses of 25 kBq/kg, 50 kBq/kg, or 80 kBq/kg. The study compared the proportion of patients in each dose group who had a confirmed decrease of greater than or equal to 50 % in baseline PSA levels. The study met its primary end-point with a statistically significant dose-response relationship being confirmed. The authors concluded that Ra-223 had a dose-dependent effect on serum markers of CRPC activity, suggesting that control of bone disease with Ra-223 may affect cancer-related outcomes.

Parker et al (2013b) also assessed the safety and effectiveness of Ra-223 in a phase III clinical trial. The investigators assessed the safety and effectiveness of Ra-223 as compared with placebo. These investigators randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive 6 injections of Ra-223 (at a dose of 50 kBq/kg intravenously) or matching placebo; 1 injection was administered every 4 weeks. Assessments of all main primary and secondary efficacy end-points also showed a benefit of Ra-223 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer AEs. The authors concluded that in this study, which was terminated for efficacy at the pre-specified interim analysis, Ra-223 improved OS.

The Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial was a phase 3, randomized, double-blind, placebo-controlled study which randomized 921 men with symptomatic bone-metastatic CRPC to six injections every week of either radium-223(50 kBq/kg) or placebo. Patients were symptomatic with two or more bone metastases, without visceral metastases and had received docetaxel or were ineligible for docetaxel treatment. Median overall survival in the radium-223 arm was 14.9 months compared to 11.2 months in the placebo arm. Median time-time-to-first skeletal related event was significantly improved in the treatment arm (13.6 months) compared to placebo (8.4 months). Time-to-alkaline-phosphatase-progression and time-to-PSA-progression was also improved in the treatment group. More adverse events were observed in the radium-223 group with discontinuation of treatment due to adverse events occurring in 13% of the men in the radium-223 and 20% of the men in the placebo arm. The significantly improved overall survival in the treatment group met the predetermined boundary for discontinuing the study early and the trial was terminated due to evidence of significant treatment benefit of radium-223. ( Hoskin et al. 2014).

Parker et al. (2017) conducted a three-year safety evaluation of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Prostate Cancer Trial. Safety analyses from phase 3 randomized Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial included patients receiving ≥1 study-drug injection (600 radium-223 and 301 placebo). Patients (405 radium-223 and 167 placebo) entered long-term safety follow-up starting 12 wk after the last study-drug injection, to 3 yr from the first injection. Forty-eight of 405 (12%) radium-223 and 12/167 (7%) placebo patients completed follow-up, with evaluations every 2 mo for 6 mo, then every 4 mo until 3 yr. Final long-term safety ALSYMPCA analysis shows that radium-223 remained well tolerated, with low myelosuppression incidence and no new safety concerns.

**Professional Societies**

**National Comprehensive Cancer Network (NCCN)**

The National Comprehensive Cancer Network’s clinical practice guideline on “Prostate cancer” (NCCN, 2017) recommends use of radium-223 as a first-line or second-line therapeutic option for CRPC in men with symptomatic bone metastases who do not have any visceral metastases. NCCN guidelines (2018) states that radium-223 is an alpha-emitting radiopharmaceutical that has shown to extend survival in men who have castrate-resistant prostate cancer with symptomatic bone metastases, but no visceral metastases.

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

In January 2018, the U.S. Food and Drug Administration approved Lutathera® (lutetium Lu 177 dotatate) for the treatment of somatostatin receptor-positive GEP-NETs in adults. This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs. Lutathera® was approved under priority review and received Orphan Drug designation. GEP-NETs can be present in the pancreas and in different parts of the gastrointestinal tract such as the stomach, intestines, colon and rectum.
The FDA granted approval of radium Ra 223 dichloride (Xofigo®) injection based on a Phase III, double-blind, randomized, placebo-controlled clinical trial. The ALSYMPCA (ALpharadin in SYMptomatic Prostate Cancer) trial included individuals with castration-resistant prostate cancer who had two or more bone metastases that were symptomatic.

**CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)**

Medicare does not have National Coverage Determinations (NCDs) specifically for radiopharmaceutical therapy. Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist; see the LCDs/LCAs for Additional Claim Documentation Requirements for Not Otherwise Classified (NOC) Drugs and Biological Products with Specific FDA Label Indications, Cardiac Radionuclide Imaging, Coding Radiopharmaceutical Agents and Xofigo Billing Instructions. (Accessed July 12, 2018)

**REFERENCES**


Bayer HealthCare Pharmaceuticals Inc. Xofigo (radium Ra 223 dichloride) Injection, for intravenous use [prescribing information]. Revised May 2013a.


**POLICY HISTORY/REVISION INFORMATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/01/2019</td>
<td>• New policy</td>
</tr>
</tbody>
</table>

**INSTRUCTIONS FOR USE**

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.